New study tests pain treatment in humans

Nerve growth factor signals through receptors of the tropomyosin-related kinase (Trk) family, and research in animals has shown that inhibitors of Trks A, B, and C can reduce pain. Now a new study in the British Journal of Clinical Pharmacology (http://bpspubs.onlinelibrary.wiley.com/hub/journal/10.1111/(ISSN)1365-2125/) provides the first demonstration of pain relief in humans using a Trk inhibitor.

The inhibitor was compared with pregabalin, ibuprofen, and placebo, in randomized, double blind, cross-over study with 20 participants.

"One striking aspect of this study is the use of a pain challenge model to assess this novel Trk mechanism. By determining the effect of a single dose of the drug in healthy subjects, we were able to provide an early demonstration of analgesia without the need to run a large patient study," said lead author Dr. Peter Loudon, of Pfizer WRD, in the UK. "Furthermore, the use of a range of different pain challenge models has provided some information on the quality of effect, which may help predict the best patient population for future studies."

Source: http://newsroom.wiley.com/press-release/british-journal-clinical-pharmacology/new-pain-treatment-tested-humans

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Vitamin K2 reduces the frequency, intensity, and duration of nighttime leg cramps